ClinicalTrials.gg
CompletedNCT00224133Updated Apr 27, 2010Results posted

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

A Phase 3 interventional study of Silodosin in Benign Prostatic Hyperplasia, sponsored by Watson Pharmaceuticals. Completed at 79 sites in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-04-27.

Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
661
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
3rd of 19
661 · median 141
Started
2005
with 2 others
Phase 3
4 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
4 of 19
Watson Pharmaceuticals

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 3rd largest by enrollment, is one of 3 that started in 2005, is one of 4 in phase 3, and was the 1st registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

Read the detailed description

This will be a multi-center, open-label 40 week investigation in up to 1,200 men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, adverse events, concomitant medications, and compliance.

All subjects had previously participated in a 12-week double-blind placebo controlled trial (NCT000224107 or NCT000224120)

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • benign prostatic hyperplasia, alpha blocker
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males in good general health and at least 50 years of age, who have completed SI04009 or SI04010.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that would confound the efficacy evaluation.
  • Medical conditions in which it would be unsafe to use an alpha-blocker.
  • The use of concomitant drugs that would confound the efficacy evaluation.
  • The use of concomitant drugs that would be unsafe with this alpha-blocker.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
661 participants (actual)

Study arms

  • Experimental
    Silodosin

    Silodosin 8 mg per day with food

    Drug: Silodosin

Interventions

  • 8 mg daily

    Also known as: Rapaflo

06

What researchers measure

Primary outcomes

  1. Adverse Events

    All reported adverse events were recorded. Clinically significant abnormal laboratory values or other clinical findings upon examination were also recorded as adverse events.

    Time frame: 9 months

Secondary outcomes

  1. International Prostate Symptom Score (IPSS)

    The IPSS is a symptom severity scale from 0 to 35 that is derived from a 7 item questionnaire. 0 indicates no symptoms and 35 indicates most severe symptoms.

    Time frame: 9 months

07

Results

Posted Apr 27, 2010

Participant flow

Participant flow — Overall Study
Milestone8 mg Silodosin Per Day With Food
Started661
Completed435
Not completed226
Withdrew: Adverse event93
Withdrew: Protocol violation6
Withdrew: Withdrawal by subject33
Withdrew: Lack of efficacy58
Withdrew: Lost to follow-up21
Withdrew: Physician decision1
Withdrew: Other14

Outcome measures

PrimaryAdverse Events

All reported adverse events were recorded. Clinically significant abnormal laboratory values or other clinical findings upon examination were also recorded as adverse events.

Time frame:
9 months
Reported as:
Number · participants
Adverse Events
participants8 mg Silodosin Per Day With Food
Patients with at least 1 adverse event431
Patients with drug related adverse event188
Patients with a serious adverse events29
Patients with a drug related serious adverse event0
Patients discontinued due to an adverse event86
Discontinued for drug related adverse event54
SecondaryInternational Prostate Symptom Score (IPSS)

The IPSS is a symptom severity scale from 0 to 35 that is derived from a 7 item questionnaire. 0 indicates no symptoms and 35 indicates most severe symptoms.

Time frame:
9 months
Reported as:
Mean · Units on a scale

Results for this outcome have not been posted.

Adverse events

Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8 mg Silodosin Per Day With Food—29/661 (4.4%)138/661 (20.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
Event8 mg Silodosin Per Day With Food
OsteoarthritisMusculoskeletal and connective tissue disorders4/661
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/661
Atrial fibrillationCardiac disorders2/661
DiverticulitisInfections and infestations2/661
Hip arthroplastySurgical and medical procedures2/661
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/661
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/661
Acute myocardial infarctionCardiac disorders1/661
AneurysmVascular disorders1/661
ArrythmiaCardiac disorders1/661
Most frequent other events
Most frequent other events
Event8 mg Silodosin Per Day With Food
Retrograde ejaculationReproductive system and breast disorders138/661

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)8 mg Silodosin Per Day With Food
<=18 years0
Between 18 and 65 years356
>=65 years305
Age Continuous
Age Continuous(years)8 mg Silodosin Per Day With Food
Mean65.0 ± 7.79
Sex: Female, Male
Sex: Female, Male(Participants)8 mg Silodosin Per Day With Food
Female0
Male661
Region of Enrollment
Region of Enrollment(participants)8 mg Silodosin Per Day With Food
United States661
08

Study locations

79 sites
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Carmichael, California, United States
  • Culver City, California, United States
  • Fresno, California, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • Laguna Woods, California, United States
  • Long Beach, California, United States
  • Newport Beach, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Tarzana, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Waterbury, Connecticut, United States
  • Aventura, Florida, United States
  • Clearwater, Florida, United States
  • Coral Gables, Florida, United States
  • New Port Richey, Florida, United States
  • Ocala, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Plantation, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Melrose Park, Illinois, United States
  • Peoria, Illinois, United States
  • Evansville, Indiana, United States
  • Fort Wayne, Indiana, United States
  • Des Moines, Iowa, United States
  • Overland Park, Kansas, United States
  • Greenbelt, Maryland, United States
  • Boston, Massachusetts, United States
  • St. Joseph, Michigan, United States
  • Edina, Minnesota, United States
  • Jackson, Mississippi, United States
  • Kansas City, Missouri, United States
  • Missoula, Montana, United States
  • Las Vegas, Nevada, United States
  • Lawrenceville, New Jersey, United States
  • Voorhees, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Bay Shore, New York, United States
  • Garden City, New York, United States
  • Kingston, New York, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Staten Island, New York, United States
  • Williamsville, New York, United States
  • Charlotte, North Carolina, United States
  • Concord, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Bethany, Oklahoma, United States
  • Portland, Oregon, United States
  • Lancaster, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Greer, South Carolina, United States
  • Mt. Pleasant, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Lakewood, Washington, United States
  • Seattle, Washington, United States
  • Tacoma, Washington, United States
  • Madison, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009 Dec;74(6):1318-22. doi: 10.1016/j.urology.2009.06.072. Epub 2009 Oct 7. PubMed 19815265 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2005
First posted
Sep 22, 2005
Start
Sep 2005
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Results first posted
Apr 27, 2010
Last update
Apr 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00224133
First posted
Sep 22, 2005
Start date
Sep 2005
Primary completion
Apr 2007
Completion
Apr 2007
Results posted
Apr 27, 2010
Last update
Apr 27, 2010

Study contacts

Lawrence Hill, Pharm D, RPh
study director · Watson Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion